{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"A 3+3 design was employed. At each dose, three patients were initially evaluated. If no dose limiting toxicities were observed, the bendamustine dose was increased; if one dose limiting toxicity is observed, three additional patients were treated at that dose. A dose at which 2 DLTs were observed in 3 or 6 patients were judged to be too toxic and the lower dose was defined as the maximally tolerated dose (MTD).","groups":[{"description":"MLN9708 : 4 mg, days 1, 8, 15.\n\nDexamethasone: 40 mg oral weekly.\n\nBendamustine: 70 mg/m\\^2 days 1 and 2","id":"OG000","title":"Bendamustine (70 mg/m^2), MLN9708, Dexamethasone"},{"description":"MLN9708 : 4 mg, days 1, 8, 15.\n\nDexamethasone: 40 mg oral weekly.\n\nBendamustine: 80 mg/m\\^2 days 1 and 2","id":"OG001","title":"Bendamustine (80 mg/m^2), MLN9708, Dexamethasone"},{"description":"MLN9708 : 4 mg, days 1, 8, 15.\n\nDexamethasone: 40 mg oral weekly.\n\nBendamustine: 90 mg/m\\^2 days 1 and 2","id":"OG002","title":"Bendamustine (90 mg/m^2), MLN9708, Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Six months","title":"Number of Participants Experiencing Dose-Limiting Toxicity (DLT)","type":"SECONDARY","unitOfMeasure":"Participants"}